Athenex (NASDAQ: ATNX)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Athenex Return vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Athenex Company Info
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
News & Analysis
The company hopes to develop cancer treatments based on individualized gene therapies, and has two promising pipeline candidates.
A blockbuster acquisition could help the biotech "convert cancer into a chronic disease."
These two companies aren't reinventing the wheel, but they still have the potential for tremendous growth.
The company announced the pricing of a public offering of common stock.
The company announced good news regarding one of its leading pipeline candidates.
Investors did not see the clinical trial results they wanted.
The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.
Promising new results in breast cancer will be presented at next week's San Antonio Breast Cancer Symposium. Here's what to look for.
ATNX earnings call for the period ending September 30, 2021.
ATNX earnings call for the period ending June 30, 2021.
ATNX earnings call for the period ending March 31, 2021.
ATNX earnings call for the period ending December 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.